Surprising conservation of schizophrenia risk genes in lower organisms reflects their essential function and the evolution of genetic liability

Schizophrenia is a devastating psychiatric illness that affects approximately 1% of the population. Genetic variation in multiple genes causes elevated risk for the disorder, but the molecular basis is inadequately understood and it is not clear how risk genes have evolved and persisted in the genome. To address these issues, we have identified orthologs/homologs of 344 schizophrenia risk genes (from the Psychiatric Genomics Consortium dataset) in lower organisms, including C. elegans, Drosophila and zebrafish, along with phenotypes produced by genetic disruption in C.
Source: Schizophrenia Research - Category: Psychiatry Authors: Source Type: research

Related Links:

ConclusionsThe present study demonstrates that R. rosea extract robustly reverses prepulse inhibition deficits in rodents. This suggests antipsychotic-like effects of R. rosea extract. Future studies should focus on the pharmacological mechanisms underlying these effects.Graphical abstract
Source: Journal of Ethnopharmacology - Category: Drugs & Pharmacology Source Type: research
Hung-Chun Chang told New Scientist about his team ’s controversial project to find drugs for depression and schizophrenia using clones of gene-edited monkeys
Source: New Scientist - Health - Category: Consumer Health News Source Type: research
Jiang Li, Hitoshi Hashimoto, Herbert Y. Meltzer
Source: Frontiers in Psychiatry - Category: Psychiatry Source Type: research
Schizophrenia is a chronic mental disorder that is still poorly understood despite decades of study. Many factors have been found to contribute to the pathogenesis, including neurodevelopmental disturbance, genetic risk, and environmental insult, but no single root cause has emerged. While evidence from twin studies suggests a strong heritable component, few individual loci have been identified in genomewide screens, suggesting a role for epigenetic effects. Rather, large numbers of weakly acting loci may cumulatively increase disease risk, including several mapping to epigenetic pathways. In this review, we discuss mechan...
Source: Molecular Neuropsychiatry - Category: Neuroscience Source Type: research
Atypical antipsychotics induce human osteoblasts apoptosis via Wnt/β-catenin signaling. BMC Pharmacol Toxicol. 2019 Feb 12;20(1):10 Authors: Li P, Wang Y, Liu X, Zhou Z, Wang J, Zhou H, Zheng L, Yang L Abstract BACKGROUND: There is evidence that atypical antipsychotics (APs) increase risk of osteoporosis in schizophrenia patients, however the mechanism is unclear. The aim of the study was to explore the molecular mechanisms about Wnt/β-catenin signal pathway underlying the osteal side effects of APs. METHODS: We cultured human osteoblast cell line hFob1. 19 (OB) treatments with olanzapine...
Source: BMC Pharmacology and Toxicology - Category: Drugs & Pharmacology Tags: BMC Pharmacol Toxicol Source Type: research
ConclusionsFor the slow and intermediate metabolizers, atypical antipsychotics determined a significant increase of prolactinemia with high risk of adverse events.
Source: Irish Journal of Medical Science - Category: General Medicine Source Type: research
Are Suicide and Addiction Linked? When someone is suffering from an issue with addiction, there are many complications that can come along with that. These can include legal issues, family problems, declining health and even suicide. Suicide and addiction are absolutely linked. Addiction not only exponentially increases the likelihood that someone will commit suicide, but substances are often used as a means to commit suicide via overdose. According to the CDC, one in three people who die from suicide are under the influence of drugs. They are typically opiates such as oxycodone or heroin, or alcohol. When someone is suffe...
Source: Cliffside Malibu - Category: Addiction Authors: Tags: Addiction Addiction Recovery Addiction Stories Addiction to Pharmaceuticals Addiction Treatment and Program Resources Depression Depression Treatment Mental Health anxiety Post Traumatic Stress Disorder PTSD suicide suicide and add Source Type: blogs
Toronto researchers believe the drug can also help those with depression, schizophrenia and Alzheimer ’sAn experimental drug that bolsters ailing brain cells has raised hopes of a treatment for memory loss, poor decision making and other mental impairments that often strike in old age.The drug could be taken as a daily pill by over-55s if clinical trials, which are expected to start within two years, show that the medicine is safe and effective at preventing memory lapses.Continue reading...
Source: Guardian Unlimited Science - Category: Science Authors: Tags: Neuroscience Memory Medical research Mental health Drugs World news Alzheimer's Society Ageing Schizophrenia Depression Canada Americas Source Type: news
Publication date: Available online 13 February 2019Source: NeuroImage: ClinicalAuthor(s): Kit Melissa Larsen, Morten Mørup, Michelle Rosgaard Birknow, Elvira Fischer, Line Olsen, Michael Didriksen, William Frans Christiaan Baaré, Thomas Mears Werge, Marta Isabel Garrido, Hartwig Roman SiebnerAbstractOne of the most common copy number variants, the 22q11.2 microdeletion, confers an increased risk for schizophrenia. Since schizophrenia has been associated with an aberrant neural response to repeated stimuli through both reduced adaptation and prediction, we here hypothesized that this may also be the case in no...
Source: NeuroImage: Clinical - Category: Radiology Source Type: research
THURSDAY, Feb. 14, 2019 -- For people with schizophrenia (PwS), wisdom is associated with better cognitive performance, according to a study published online Feb. 14 in Schizophrenia Research. Ryan Van Patten, Ph.D., from the University of...
Source: Drugs.com - Pharma News - Category: Pharmaceuticals Source Type: news
More News: Genetics | Psychiatry | Schizophrenia